147 related articles for article (PubMed ID: 38341302)
21. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
Kurt H; Bueso-Ramos CE; Khoury JD; Routbort MJ; Kanagal-Shamanna R; Patel UV; Jorgensen JL; Wang SA; Ravandi F; DiNardo C; Luthra R; Medeiros LJ; Patel KP
Am J Surg Pathol; 2018 May; 42(5):569-577. PubMed ID: 29635257
[TBL] [Abstract][Full Text] [Related]
22. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical correlates of TP53 somatic mutations in cancer.
Murnyák B; Hortobágyi T
Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia.
Sawada K; Momose S; Kawano R; Kohda M; Irié T; Mishima K; Kaneko T; Horie N; Okazaki Y; Higashi M; Tamaru JI
Mod Pathol; 2022 Feb; 35(2):177-185. PubMed ID: 34404905
[TBL] [Abstract][Full Text] [Related]
25.
Thiel KW; Devor EJ; Filiaci VL; Mutch D; Moxley K; Alvarez Secord A; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Aghajanian C; Samuelson MI; Lankes HA; Soslow RA; Leslie KK
J Clin Oncol; 2022 Oct; 40(28):3289-3300. PubMed ID: 35658479
[TBL] [Abstract][Full Text] [Related]
26. Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.
Venugopal S; Loghavi S
Pathobiology; 2024; 91(1):45-54. PubMed ID: 37839402
[TBL] [Abstract][Full Text] [Related]
27. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
Hwang HJ; Nam SK; Park H; Park Y; Koh J; Na HY; Kwak Y; Kim WH; Lee HS
J Pathol Transl Med; 2020 Sep; 54(5):378-386. PubMed ID: 32601264
[TBL] [Abstract][Full Text] [Related]
28. Utilizing digital pathology and immunohistochemistry of p53 as an adjunct to molecular testing in myeloid disorders.
Rogers KJ; Abukhiran IM; Syrbu S; Tomasson M; Bates M; Dhakal P; Bhagavathi S
Acad Pathol; 2023; 10(1):100064. PubMed ID: 36970330
[No Abstract] [Full Text] [Related]
29. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Kubesova B; Pavlova S; Malcikova J; Kabathova J; Radova L; Tom N; Tichy B; Plevova K; Kantorova B; Fiedorova K; Slavikova M; Bystry V; Kissova J; Gisslinger B; Gisslinger H; Penka M; Mayer J; Kralovics R; Pospisilova S; Doubek M
Leukemia; 2018 Feb; 32(2):450-461. PubMed ID: 28744014
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.
Fernandez-Pol S; Ma L; Ohgami RS; Arber DA
Mod Pathol; 2017 Mar; 30(3):382-392. PubMed ID: 27934876
[TBL] [Abstract][Full Text] [Related]
31. A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.
Kato H; Maezawa Y; Nishijima D; Iwamoto E; Takeda J; Kanamori T; Yamaga M; Mishina T; Takeda Y; Izumi S; Hino Y; Nishi H; Ishiko J; Takeuchi M; Kaneko H; Koshizaka M; Mimura N; Kuzuya M; Sakaida E; Takemoto M; Shiraishi Y; Miyano S; Ogawa S; Iwama A; Sanada M; Yokote K
Exp Hematol; 2022 May; 109():11-17. PubMed ID: 35240258
[TBL] [Abstract][Full Text] [Related]
32.
Ball S; Loghavi S; Zeidan AM
Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
[TBL] [Abstract][Full Text] [Related]
33. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
[TBL] [Abstract][Full Text] [Related]
35. Genomic landscape of TP53-mutated myeloid malignancies.
Abel HJ; Oetjen KA; Miller CA; Ramakrishnan SM; Day RB; Helton NM; Fronick CC; Fulton RS; Heath SE; Tarnawsky SP; Nonavinkere Srivatsan S; Duncavage EJ; Schroeder MC; Payton JE; Spencer DH; Walter MJ; Westervelt P; DiPersio JF; Ley TJ; Link DC
Blood Adv; 2023 Aug; 7(16):4586-4598. PubMed ID: 37339484
[TBL] [Abstract][Full Text] [Related]
36. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract][Full Text] [Related]
37. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
[TBL] [Abstract][Full Text] [Related]
38. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
